| Bid | 1.04 |
| Market Cap | 27.05M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.59 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 1.28 |
| Volume | 34,125 |
| Avg. Volume (20D) | 67,311 |
| Open | 1.16 |
| Previous Close | 1.13 |
| Day's Range | 1.06 - 1.16 |
| 52-Week Range | 0.73 - 3.05 |
| Beta | undefined |
About AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also prov...
Analyst Forecast
According to 1 analyst ratings, the average rating for AXDX stock is "Hold." The 12-month stock price forecast is $1, which is a decrease of -7.41% from the latest price.
Next Earnings Release
Analysts project revenue of $3.00M, reflecting a -0.89% YoY shrinking and earnings per share of -0.5, making a -43.82% decrease YoY.
2 months ago · seekingalpha.com
Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call TranscriptAccelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and C...
